Skip to content
  • Sunday, 26 July 2026
  • 3:05 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Engineered exosomes from pig semen: a high-yield platform for non-invasive ocular drug delivery
Laboratory Automation & Robotics

Engineered exosomes from pig semen: a high-yield platform for non-invasive ocular drug delivery

Lana Keisha May 11, 2026 0

In a remarkable breakthrough in ocular pharmacology, researchers in China have pioneered the development of novel eye drops derived from…

Read More
Laboratory Automation & Robotics

Engineered exosomes from pig semen: a high-yield platform for non-invasive ocular drug delivery

Lana Keisha May 3, 2026 0

Researchers in China have achieved a significant breakthrough in ophthalmic pharmacology, developing innovative eye drops derived from pig semen that…

Read More
Laboratory Automation & Robotics

Revolutionary Eye Drops Derived from Pig Semen Show Promise for Non-Invasive Ocular Cancer Treatment

Lana Keisha Apr 26, 2026 0

A groundbreaking study published in Science Advances reveals that researchers in China have successfully engineered eye drops utilizing exosomes derived…

Read More
Laboratory Automation & Robotics

Engineered exosomes from pig semen: a high-yield platform for non-invasive ocular drug delivery

Lana Keisha Apr 16, 2026 0

Chinese researchers have unveiled a groundbreaking approach to treating ocular cancers, specifically retinoblastoma, through the development of specialized eye drops…

Read More
Laboratory Automation & Robotics

Engineered exosomes from pig semen: a high-yield platform for non-invasive ocular drug delivery

Lana Keisha Apr 9, 2026 0

Researchers in China have achieved a significant breakthrough in ophthalmic pharmacology, developing innovative eye drops derived from pig semen that…

Read More
Laboratory Automation & Robotics

Engineered exosomes from pig semen: a high-yield platform for non-invasive ocular drug delivery

Lana Keisha Apr 2, 2026 0

In a groundbreaking development that could revolutionize the treatment of ocular cancers, researchers in China have successfully engineered eye drops…

Read More
OpenClaw Revolutionizes Personal AI with Local LLM Integration Across Messaging PlatformsGoogle Unveils Conductor: Revolutionizing AI-Assisted Development with Context-Driven WorkflowDAMPE Telescope Unveils Universal Pattern in High-Energy Cosmic Rays Challenging Existing Astrophysical ModelsWater drops on soap bubble films act like merging galaxies
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ